SEARCH

SEARCH BY CITATION

References

  • 1
    Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. Oncogene 2004; 23: 652434.
  • 2
    Chiu BC, Weisenburger DD. An update of the epidemiology of non-Hodgkin's lymphoma. Clin Lymphoma 2003; 4: 1618.
  • 3
    Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5 version 2.0. Lyon: IARC Press, 2004.
  • 4
    A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 390918.
  • 5
    Archuleta TD, Armitage JO. Advances in follicular lymphoma. Semin Oncol 2004; 31 ( Suppl 4): 6671.
  • 6
    Maloney DG. Treatment of follicular non-Hodgkin's lymphoma. Curr Hematol Rep 2005; 4: 3945.
  • 7
    Buske C, Dreyling H, Unterhalt M, Hiddemann W. Novel treatment strategies in follicular lymphoma. Ann Hematol 2004; 83 ( Suppl 1): S72.
  • 8
    Zinzani PL. Traditional treatment approaches in B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 2003; 44 ( Suppl 4): S614.
  • 9
    Zinzani PL, Pulsoni A, Perrotti A, Soverini S, Zaja F, De Renzo A, Storti S, Lauta VM, Guardigni L, Gentilini P, Tucci A, Molinari AL, et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 2004; 22: 265461.
  • 10
    Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, Solal-Celigny P, Offner F, Walewski J, Raposo J, Jack A, Smith P. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 141723.
  • 11
    Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Klippenstein D, Dallaire B, Varns C. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 26876.
  • 12
    Czuczman MS, Koryzna A, Mohr A, Stewart C, Donohue K, Blumenson L, Bernstein ZP, McCarthy P, Alam A, Hernandez-Ilizaliturri F, Skipper M, Brown K, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005; 23: 694704.
  • 13
    Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, Regan D, Kison P, Fisher S, Kroll S, Wahl RL. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352: 4419.
  • 14
    Lenz G, Hiddemann W, Dreyling M. The role of fludarabine in the treatment of follicular and mantle cell lymphoma. Cancer 2004; 101: 88393.
  • 15
    Hainsworth JD, Litchy S, Morrissey LH, Andrews MB, Grimaldi M, McCarty M, Greco FA. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005; 23: 15006.
  • 16
    Herold M, Pasold R, Srock S, Neser S, Niederwieser D, Neubauer A, Dolken G, Naumann R, Fietz T, Knauf W, Freund M, Rohrberg R, et al. Rituximab plus mitoxantrone, chlorambucil, prednisolon (R-MCP) is superior to MCP alone in advanced indolent and follicular lymphoma—results of a phase III study (OSH039). Ann Oncol 2005; 16: v512. Abstract 060.
  • 17
    Lenz G, Dreyling M, Hiddemann W. Mantle cell lymphoma: established therapeutic options and future directions. Ann Hematol 2004; 83: 717.
  • 18
    Hiddemann W, Dreyling M. Mantle cell lymphoma: therapeutic strategies are different from CLL. Curr Treat Options Oncol 2003; 4: 21926.
  • 19
    Kauh J, Baidas SM, Ozdemirli M, Cheson BD. Mantle cell lymphoma: clinicopathologic features and treatments. Oncology (Williston Park) 2003; 17: 87991,96; discussion 96–8.
  • 20
    Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B, Pott C, Hartmann F, Rothmann F, Rohrberg R, Bock HP, Wandt H, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 306471.
  • 21
    Lenz G, Dreyling M, Hoster E, Wormann B, Duhrsen U, Metzner B, Eimermacher H, Neubauer A, Wandt H, Steinhauer H, Martin S, Heidemann E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23: 198492.
  • 22
    Marcus R. Current treatment options in aggressive lymphoma. Leuk Lymphoma 2003; 44 ( Suppl 4): S1527.
  • 23
    Khouri IF, Romaguera J, Kantarjian H, Palmer JL, Pugh WC, Korbling M, Hagemeister F, Samuels B, Rodriguez A, Giralt S, Younes A, Przepiorka D, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998; 16: 38039.
  • 24
    Geisler CH, Elonen E, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, Nordstroem M, Lauritzen GF, Ralfkiaer E, Aakerman M, Sundstroem C, et al. Nordic mantle cell lymphoma (MCL) project: prolonged follow-up of 86 patients treated with BEAM/BEAC + PBSCT confirms that addition of high-dose Ara-C and rituximab to CHOP induction + in-vivo purging with rituximab increases clinical and molecular response rates, PCR-neg. grafts, failure-free, relapse-free and overall survival. Blood 2004; 104: 6a. Abstract 8.
  • 25
    Fisher RI. Mantle cell lymphoma: at last, some hope for successful innovative treatment strategies. J Clin Oncol 2005; 23: 6578.
  • 26
    Coiffier B. Treatment of diffuse large B-cell lymphoma. Curr Hematol Rep 2005; 4: 714.
  • 27
    Fisher RI, Miller TP, O'Connor OA. Diffuse aggressive lymphoma. Hematology (Am Soc Hematol Educ Program) 2004: 22136.
  • 28
    Bjorkholm M. Treatment options in Waldenstrom's macroglobulinemia. Clin Lymphoma 2004; 5: 15562.
  • 29
    Adams J, Kauffman M. Development of the proteasome inhibitor velcade (bortezomib). Cancer Invest 2004; 22: 30411.
  • 30
    Schenkein D. Proteasome inhibitors in the treatment of B-cell malignancies. Clin Lymphoma 2002; 3: 4955.
  • 31
    Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 261522.
  • 32
    Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004; 4: 34960.
  • 33
    Burger AM, Seth AK. The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. Eur J Cancer 2004; 40: 221729.
  • 34
    Myung J, Kim KB, Crews CM. The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev 2001; 21: 24573.
  • 35
    Voorhees PM, Dees EC, O'Neil B, Orlowski RZ. The proteasome as a target for cancer therapy. Clin Cancer Res 2003; 9: 631625.
  • 36
    Goy A, Gilles F. Update on the proteasome inhibitor bortezomib in hematologic malignancies. Clin Lymphoma 2004; 4: 2307.
  • 37
    DeMartino GN, Slaughter CA. The proteasome, a novel protease regulated by multiple mechanisms. J Biol Chem 1999; 274: 221236.
  • 38
    Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001; 8: 73958.
  • 39
    Hideshima T, Richardson PG, Anderson KC. Targeting proteasome inhibition in hematologic malignancies. Rev Clin Exp Hematol 2003; 7: 191204.
  • 40
    Adams J, Palombella VJ, Elliott PJ. Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs 2000; 18: 10921.
  • 41
    Adams J. Potential for proteasome inhibition in the treatment of cancer. Drug Discov Today 2003; 8: 30715.
  • 42
    Richardson PG, Hideshima T, Anderson KC. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 2003; 10: 3619.
  • 43
    Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995; 270: 28690.
  • 44
    Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS,Jr. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995; 270: 2836.
  • 45
    Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 2000; 164: 22006.
  • 46
    Romano MF, Lamberti A, Tassone P, Alfinito F, Costantini S, Chiurazzi F, Defrance T, Bonelli P, Tuccillo F, Turco MC, Venuta S. Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells. Blood 1998; 92: 9905.
  • 47
    Leitch D, Barrans SL, Jack AS, Owen RG. Dysregulation of apoptosis in Waldenstrom's macroglobulinemia does not involve nuclear factor kappa B activation. Semin Oncol 2003; 30: 1614.
  • 48
    Mori N, Fujii M, Ikeda S, Yamada Y, Tomonaga M, Ballard DW, Yamamoto N. Constitutive activation of NF-kappaB in primary adult T-cell leukemia cells. Blood 1999; 93: 23608.
  • 49
    Portis T, Harding JC, Ratner L. The contribution of NF-kappa B activity to spontaneous proliferation and resistance to apoptosis in human T-cell leukemia virus type 1 Tax-induced tumors. Blood 2001; 98: 12008.
  • 50
    Liebowitz D. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med 1998; 338: 141321.
  • 51
    Keller SA, Schattner EJ, Cesarman E. Inhibition of NF-kappa B induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 2000; 96: 253742.
  • 52
    Liu L, Eby MT, Rathore N, Sinha SK, Kumar A, Chaudhary PM. The human herpes virus 8-encoded viral FLICE inhibitory protein physically associates with and persistently activates the Ikappa B kinase complex. J Biol Chem 2002; 277: 1374551.
  • 53
    Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, Grenier L, Klunder JM, Ma YT, Plamondon L, Stein RL. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 1998; 8: 3338.
  • 54
    Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 30716.
  • 55
    Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, Schlossman R, Podar K, Munshi NC, Mitsiades N, Anderson KC. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003; 101: 15304.
  • 56
    LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J, Gupta D, Richardson PG, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002; 62: 49965000.
  • 57
    Yang Y, Ikezoe T, Saito T, Kobayashi M, Koeffler HP, Taguchi H. Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. Cancer Sci 2004; 95: 17680.
  • 58
    Ling YH, Liebes L, Jiang JD, Holland JF, Elliott PJ, Adams J, Muggia FM, Perez-Soler R. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 2003; 9: 114554.
  • 59
    Mortenson MM, Schlieman MG, Virudachalam S, Bold RJ. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line. Cancer Chemother Pharmacol 2004; 54: 34353.
  • 60
    Schenkein DP. Use of proteasome inhibition in the treatment of lung cancer. Clin Lung Cancer 2004; 6 ( Suppl 2): S8996.
  • 61
    Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003; 171: 8895.
  • 62
    An J, Sun Y, Fisher M, Rettig MB. Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia 2004; 18: 1699704.
  • 63
    Matta H, Chaudhary PM. The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells. Cancer Biol Ther 2005; 4: 7782.
  • 64
    Maharaj L, Strauss S, Stec J, Lister T, Joel S. Mantle cell and follicular lymphoma samples demonstrate differeing sensitivity to bortezomib in a primary culture system. Blood 2004; 104: 900a. Abstract 3294.
  • 65
    Chiarle R, Budel LM, Skolnik J, Frizzera G, Chilosi M, Corato A, Pizzolo G, Magidson J, Montagnoli A, Pagano M, Maes B, De Wolf-Peeters C, et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 2000; 95: 61926.
  • 66
    Hutter G, Zimmermann Y, Rieken M, Weinkauf M, Weigert O, Hiddemann W, Dreyling M. Cell cycle dysregulation represents an early effect of proteasome inhibitor bortezomib in mantle cell lymphoma. Blood 2004; 104: 629a. Abstract 2287.
  • 67
    Pham L, Tamayo AT, Lo P, Yoshimura L, Ford R. Antitumor activity of the proteasome inhibitor PS-341 in mantle cell lymphoma B cells. Blood 2001; 98: 465a. Abstract 1945.
  • 68
    Satou Y, Nosaka K, Koya Y, Yasunaga JI, Toyokuni S, Matsuoka M. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia 2004; 18: 135763.
  • 69
    Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Schlossman R, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101: 237780.
  • 70
    Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, Wu ZQ, Borad MJ, Frantzen M, Roussos E, Neeser J, Mikail A, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003; 9: 113644.
  • 71
    Nawrocki ST, Sweeney-Gotsch B, Takamori R, McConkey DJ. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2004; 3: 5970.
  • 72
    Denlinger CE, Rundall BK, Keller MD, Jones DR. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis. Ann Thorac Surg 2004; 78: 120714; discussion 7–14.
  • 73
    Gumerlock P, Kawaguchi T, Moisan L, Lau A, Mack P, Lara P,Jr, Gandara D. Mechanisms of enhanced cytotoxicity from docetaxel/PS-341 combination in non-small cell lung carcinoma (NSCLC). Proc Am Soc Clin Oncol 2002; 21: 304a,1214.
  • 74
    Denlinger CE, Rundall BK, Jones DR. Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species. J Thorac Cardiovasc Surg 2004; 128: 7408.
  • 75
    Goy A, Remache Y, Barkoh B, Jiang Y, Hart S, Gilles F. Sensitivity, schedule-dependence and molecular effects of the proteasome inhibitor bortezomib in non-Hodgkin's lymphoma cells. Blood 2004; 104: 389a90a. Abstract 1387.
  • 76
    De Vos S, McBride W, Calimlim J, Koeffler H, Said J, Perwan M. Active combination therapy of bortezomib and rituximab in an in vitro and in vivo DLBCL model. Proc AACR 2004; 45:Abstract 546.
  • 77
    Lewintre EJ, Sarsotti E, Terol MJ, Benet I, Martinez-Climent JA, Garcia-Conde J. Treatment of B-CLL cells with bortezomib and rituximab reduces cell viability in vitro. Blood 2004; 104: 765a6a. Abstract 2798.
  • 78
    Smolewski P, Duechler M, Linke A, Cebula B, Schwarzmeier JD, Robak T. Cytotoxic effect of proteasome inhibitor bortezomib in combination with ourine nucleoside analogues on chronic lymphocytic leukemis cells in vitro. Blood 2004; 104: 288b. Abstract 4822.
  • 79
    Smith M, Jin F, Joshi I. Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to TRAIL receptors TRAIL-R1 and TRAIL-R2. Blood 2004; 104: 237b. Abstract 4614.
  • 80
    O'Connor O, Toner L, Smith E, Srinivasan S, Hernandez F, Rolf M, Frankel S, Chanan-Khan A. Combined targeting of the proteasome and Bcl-2 sensitizes human B-cell lymphoma and multiple myeloma to cyclophosphamide in in vitro and in vivo models of these diseases. Blood 2004; 104: 681a. Abstract 2484.
  • 81
    Russo SM, Tepper JE, Baldwin AS,Jr, Liu R, Adams J, Elliott P, Cusack JC,Jr. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 2001; 50: 18393.
  • 82
    O'Connor O, Wright J, Moskowitz C, MacGregor-Cortelli B, Straus D, Evans A, Winter J, Koc O, Horvath N, Blumel S, Vose J, Schenkein D, et al. A multicenter experience with single agent bortezomib in non-Hodgkin's lymphoma reveals marked differences in sub-type sensitivity to proteasome inhibition. Blood 2004; 104: 175a. Abstract 607.
  • 83
    Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 66775.
  • 84
    Goy A, Bernstein S, Kahl B, Epner E, Leonard JP, Stadtmauer E, Morgan D, Belt R, Baidas S, Fisher RI. Bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL): preliminary results of the PINNACLE study. J Clin Oncol 2005; 23: 6563 (Abstract). Updated poster presented at the 2005 Annual Meeting of the American Society of Clinical Oncology, May 13–17, 2005, Orlando, FL, USA.
  • 85
    Strauss SJ, Maharaj L, Stec J, Boral A, Trehu E, Schenkein D, Johnson P, Joel SP, TA L. Phase II clinical study of bortezomib (velcade) in patients with relapsed/ refractory non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD). Blood 2004; 104:Abstract 1386. Updated poster presented at the 46th Annual Meeting of the American Society of Hematology; December 4–7, 2004; San Diego, CA, USA.
  • 86
    Belch A, Kouroukis C, Crump M, Sehn L, Gascoyne R, Klasa R, Jean P, Eisenhauer E. Phase II trial of bortezomib in mantle cell lymphoma. Blood 2004; 104: 175a. Abstract 608. Updated data presented at the 46th Annual Meeting of the American Society of Hematology; December 4–7, 2004; San Diego, CA, USA.
  • 87
    Chen C, White D, Kouroukis C, Stewart A, Howson-Jan K, Larratt L, Powers J, Eisenhauer E. Antitumor activity of bortezomib (PS-341; velcade) in a phase II study of patients with previously untreated or treated Waldenstrom's macroglobulinemia (WM). Blood 2004; 104: 896a. Abstract 3278. Updated poster presented at the 46th Annual Meeting of the American Society of Hematology; December 4–7, 2004; San Diego, CA, USA.
  • 88
    Faderl S, Rai K, Gribben J, Flinn I, Byrd J, McConkey D, Schenkein D, Esseltine D, Browning M, Keating M. Phase 2 study of three doses of single agent bortezomib in patients with fludarabine-refractory B-cell CLL. Blood 2004; 104: 293b. Abstract 4841.
  • 89
    Saleh M, Dakhil S, deVos S, Patel-Donnelly D, Glenn M, Hart L, Reese D, Gregory S, Holladay S, McLaughlin P, Zhang T, Boral A, et al. Phase 2 study of bortezomib and rituximab in patients with indolent non-Hodgkin's lymphoma (NHL). Ann Oncol 2005; 16: v136. Updated poster presented at the 9th International Conference on Malignant Lymphoma, June 8–11, 2005, Lugano, Switzerland.
  • 90
    Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T, Johri AR, Jones PE, Ivanova A, Van Deventer HW, Gabriel DA, Shea TC, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105: 305865.
  • 91
    Dunleavy K, Janik J, Gea-Banacloche J, Shovlin M, White T, Goldschmidt N, Grant N, Koc O, Pittaluga S, Jaffe E, Staudt L, Wilson W. Phase I/II study of bortezomib alone and bortezomib with dose-adjusted EPOCH chemotherapy in relapsed or refractory aggressive B-cell lymphoma. Blood 2004; 104: 389a. Abstract 1385. Updated poster presented at the 46th Annual Meeting of the American Society of Hematology; December 4–7, 2004; San Diego, CA, USA.
  • 92
    Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, Agrawal S, Stec J, Schenkein D, Esseltine DL, Cavenagh JD. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005; 129: 75562.
  • 93
    Harousseau J, Attal M, Coiteux V, Stoppa A, Hulin C, Benboubker L, Fuzibet J, Renaud M. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: preliminary results of an IFM phase II study. J Clin Oncol 2005; 23 (Part I): 598s. Abstract 6653.
  • 94
    Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, Lowe A, Kunkel LA, Fisher RI. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001; 19: 38997.
  • 95
    Hainsworth JD, Litchy S, Burris HA,III, Scullin DC,Jr, Corso SW, Yardley DA, Morrissey L, Greco FA. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 42617.
  • 96
    Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, Guerciolini R, Anderson JK, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002; 20: 44207.
  • 97
    Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, Sabbatini P, Miller V, Hensley ML, Pezzulli S, Canales C, Daud A, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002; 8: 250511.
  • 98
    Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 260917.
  • 99
    Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Adams J, Kauffman M, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127: 16572.
  • 100
    Richardson P, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, Dalton W, Harousseau J, San Miguel J, Anderson K. Bortezomib vs dexamethasone in relapsed multiple myeloma: a phase 3 randomized study. J Clin Oncol 2004; 22: 558. Abstract 6511.
  • 101
    O'Connor OA, Wright J, Moskowitz C, Muzzy J, Macgregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, Dumetrescu O, Esseltine D, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23: 67684.
  • 102
    Assouline S, Belch A, Sehn L, Kouroukis C, Gascoyne R, Meyer R, Powers J, Eisenhauer E. A phase II study of bortezomib in patients with mantle cell lymphoma. Blood 2003; 102: 902a3a. Abstract 3358.
  • 103
    Berenson J, Yang H, Swift R, Sadler K, Vescio R, Adams J, Schenkein D. Bortezomib in combination with melphalan in the treatment of relapsed or refractory multiple myeloma: a phase I/II study. Blood. 2004; 104: 64a. Abstract 209.
  • 104
    Chanan-Khan AA, Miller KC, McCarthy P, DiMiceli LA, Yu J, Bernstein ZP, Czuczman MS. Phase II study of velcade and doxil in combination with low-dose thalidomide (VDT) as salvage therapy for patients with relapsed or refractory multiple myeloma or Waldenstrom's macroglobulinemia. Blood 2004: 665a. Abstract 2421.
  • 105
    Campbell RA, Chen H, Zhu D, Santos JC, Bonavida B, Pang S, Said J, Berenson JR. Arsenic trioxide shows synergistic anti-myeloma effects when combined with bortezomib and melphalan in vitro and helps overcome resistance of multiple myeloma cells to these treatments in vivo. Blood 2004; 104: 677a. Abstract 2467.